دورية أكاديمية
Advancing cytomegalovirus prevention in solid organ transplant recipients: The promise of cell-mediated immune assays.
| العنوان: | Advancing cytomegalovirus prevention in solid organ transplant recipients: The promise of cell-mediated immune assays. |
|---|---|
| المؤلفون: | Beechar VB; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA., Phadke VK; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA., Pouch SM; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA., Woodworth MH; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA. |
| المصدر: | Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2024 Apr; Vol. 26 (2), pp. e14245. Date of Electronic Publication: 2024 Jan 31. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Munksgaard Country of Publication: Denmark NLM ID: 100883688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1399-3062 (Electronic) Linking ISSN: 13982273 NLM ISO Abbreviation: Transpl Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Copenhagen : Munksgaard, c1999- |
| مواضيع طبية MeSH: | Cytomegalovirus Infections*/drug therapy , Organ Transplantation*/adverse effects, Humans ; Antiviral Agents/therapeutic use ; Cytomegalovirus ; CD8-Positive T-Lymphocytes ; Transplant Recipients |
| مستخلص: | Cytomegalovirus (CMV) infections are a major source of morbidity and mortality in solid organ transplant recipients. Prophylactic, preemptive, and hybrid prevention strategies have traditionally been the mainstay of CMV prevention but there is growing interest in the use of CMV cell-mediated immune assays to inform novel approaches to risk stratification. Recent evidence suggests that CMV interferon-gamma release assays can offer predictive insights into the risk for CMV-related illnesses, raising the potential for tailored CMV prevention strategies anchored to each individual's unique CMV immune profile. However, the predictive capacity of these assays for CMV-related illnesses can be profoundly influenced by when they are performed relative to transplant, and the induction immunosuppressive regimen the patient has received. In this review, we explore the relevant literature shaping our understanding of the optimal use of these assays. Furthermore, we also highlight the benefits of quantifying the CD4+ and CD8+ T-Cell responses to CMV, which is offered by some interferon-gamma release assays utilizing intracellular cytokine staining, for providing a holistic assessment of the recovery of cell-mediated immunity post-induction immunosuppression. (© 2024 Wiley Periodicals LLC.) |
| References: | Transplantation. 1999 Apr 15;67(7):1011-8. (PMID: 10221486) Clin Infect Dis. 2013 Mar;56(6):817-24. (PMID: 23196955) J Med Virol. 2018 Oct;90(10):1620-1628. (PMID: 29797330) PLoS One. 2017 Dec 12;12(12):e0189488. (PMID: 29232714) JAMA. 2020 Apr 14;323(14):1378-1387. (PMID: 32286644) Am J Transplant. 2009 May;9(5):1214-22. (PMID: 19422346) Clin Infect Dis. 2020 Dec 3;71(9):2386-2388. (PMID: 32076699) Am J Transplant. 2006 Oct;6(10):2356-64. (PMID: 16889599) Am J Transplant. 2019 Sep;19(9):2505-2516. (PMID: 30768834) Clin Infect Dis. 1995 May;20(5):1346-53. (PMID: 7620022) Clin Infect Dis. 2020 Dec 3;71(9):2375-2385. (PMID: 32076718) Clin Infect Dis. 2004 Nov 1;39(9):1293-9. (PMID: 15494905) Clin Infect Dis. 2009 Oct 15;49(8):1167-8. (PMID: 19751150) Transplant Proc. 1998 Sep;30(6):2859-60. (PMID: 9745599) Am J Med. 1997 Aug;103(2):106-13. (PMID: 9274893) Clin Infect Dis. 2022 Mar 9;74(5):757-765. (PMID: 34228099) Am J Transplant. 2013 Jul;13(7):1793-805. (PMID: 23711167) Drugs. 2018 Jul;78(11):1085-1103. (PMID: 29961185) Rev Med Virol. 2006 Sep-Oct;16(5):289-95. (PMID: 16888821) Nephrol Dial Transplant. 2017 Oct 1;32(10):1601-1608. (PMID: 27798202) Am J Transplant. 2020 Aug;20(8):2070-2080. (PMID: 31991045) J Clin Microbiol. 2022 Aug 17;60(8):e0171621. (PMID: 35543099) Transplantation. 2018 Nov;102(11):1787-1788. (PMID: 30130324) Transplantation. 1997 Nov 27;64(10):1432-7. (PMID: 9392307) Transplantation. 2018 Jun;102(6):900-931. (PMID: 29596116) |
| معلومات مُعتمدة: | K23 AI144036 United States AI NIAID NIH HHS; UL1TR002378 United States TR NCATS NIH HHS; TL1 TR002382 United States TR NCATS NIH HHS; UL1 TR002378 United States TR NCATS NIH HHS; TL1TR002382 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: CMV; cell‐mediated immune assays |
| المشرفين على المادة: | 0 (Antiviral Agents) |
| تواريخ الأحداث: | Date Created: 20240131 Date Completed: 20240412 Latest Revision: 20240425 |
| رمز التحديث: | 20240425 |
| مُعرف محوري في PubMed: | PMC11009072 |
| DOI: | 10.1111/tid.14245 |
| PMID: | 38291882 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1399-3062 |
|---|---|
| DOI: | 10.1111/tid.14245 |